CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04851119
Title field or adapter rule: {'original_value': 'A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:27.035335+00:00
Published At: 2026-08-25T00:00:00+00:00
Record Updated At: 2026-08-25
Source Retrieved At: 2026-10-31T22:17:58.991924+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Colorectal Carcinoma", "Endometrial Carcinoma", "Melanoma", "Neuroblastoma", "Ovarian Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Recurrent Desmoid Fibromatosis", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Refractory Desmoid Fibromatosis", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Hepatocellular Carcinoma", "Refractory Malignant Solid Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Solid Pseudopapillary Neoplasm of the Pancreas", "Wilms Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-08-25", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT04851119"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Treatment (tegavivint)'], 'description': 'Undergo blood sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (tegavivint)'], 'description': 'Undergo DEXA scan', 'name': 'Dual X-ray Absorptiometry', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (tegavivint)'], 'description': 'Given IV', 'name': 'Tegavivint', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (tegavivint)'], 'description': 'Undergo x-ray imaging', 'name': 'X-Ray Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.